This is a match-making section for OHAMR Call for proposals 2026.
H - Human Health
Immune-engaging antimicrobials; Lytic peptides; Dendrimers; Gram-negative pathogens; Combination therapy; Resistance suppression; Preclinical development.
We urgently seek a laboratory with established animal models of sepsis caused by Klebsiella pneumoniae and Pseudomonas aeruginosa. Your expertise will validate models for novel combination therapies under Topic 1. Pre-proposal deadline: Feb 2, 2026. Contact: José A García Salcedo jags@genyo.es.
The project targets developing resistance-resilient antimicrobial candidates against Klebsiella pneumoniae (Kp) and Pseudomonas aeruginosa (Pa) through immune-engaging and membrane-disruptive strategies, advancing to preclinical proof-of-concept for partnering. It aligns with EUP OHAMR 2026 Topic 1 on combination treatments to combat AMR. Structured across five work packages (WPs), it emphasizes synergy, safety, and translational readiness over 36 months.
Submitted on 2026-01-16 12:34:11
« Return to the partner search tool